Arca
Skip to content
Tools
Tools

-lisib

A PI3K inhibitor, blocking phosphoinositide 3-kinase; used in some blood and breast cancers.

  • Drugs ending in -lisib: 38
  • Approved somewhere: 7
  • With a US drug page: 8

What it means

Stem from WHO's stem book, 2024; description by Arca
Stem
-lisib
Class
Drugs that block PI3 kinase, mostly for cancer
Most common targets
PI3-kinase class I (15), PIK3CD (11), MTOR (7), PIK3CA (4), PIK3CG (3), CSNK1E (1), ABL1 (1), ACVRL1 (1)

Drugs that carry it

Approved and clinical-stage drugs in ChEMBL whose names ending in -lisib, matched by spelling; those with a US drug page link to it.
Acts on
AlpelisibApprovedPIK3CAPI3-kinase p110-alpha subunit inhibitor
CopanlisibApprovedPIK3CA, PIK3CDPI3-kinase p110-alpha subunit inhibitor
DuvelisibApprovedPIK3CD, PIK3CGPI3-kinase p110-delta subunit inhibitor
IdelalisibApprovedPIK3CDPI3-kinase p110-delta subunit inhibitor
InavolisibApprovedPIK3CAPI3-kinase p110-alpha subunit inhibitor
LeniolisibApprovedPIK3CDPI3-kinase p110-delta subunit inhibitor
UmbralisibApprovedPIK3CD, CSNK1E, ABL1PI3-kinase p110-delta subunit inhibitor
GedatolisibPhase 3MTOR, PI3-kinase class ISerine/threonine-protein kinase mTOR inhibitor
BuparlisibPhase 3PI3-kinase class IPI3-kinase class I inhibitor
DactolisibPhase 3MTOR, PI3-kinase class ISerine/threonine-protein kinase mTOR inhibitor
ParsaclisibPhase 3PIK3CDPI3-kinase p110-delta subunit inhibitor
TaselisibPhase 3PI3-kinase class IPI3-kinase class I inhibitor
ZandelisibPhase 3PIK3CDPI3-kinase p110-delta subunit inhibitor
AmdizalisibPhase 2——
ApitolisibPhase 2MTOR, PI3-kinase class ISerine/threonine-protein kinase mTOR inhibitor
BimiralisibPhase 2——
BosmolisibPhase 2——
GilmelisibPhase 2——
IzorlisibPhase 2PI3-kinase class IPI3-kinase class I inhibitor
LinperlisibPhase 2——
NemiralisibPhase 2PIK3CDPI3-kinase p110-delta subunit inhibitor
PaxalisibPhase 2PI3-kinase class IPI3-kinase class I inhibitor
PictilisibPhase 2PI3-kinase class IPI3-kinase class I inhibitor
PilaralisibPhase 2PI3-kinase class IPI3-kinase class I inhibitor
RisovalisibPhase 2——
RoginolisibPhase 2——
SamotolisibPhase 2MTOR, PI3-kinase class ISerine/threonine-protein kinase mTOR inhibitor
SeletalisibPhase 2PIK3CDPI3-kinase p110-delta subunit inhibitor
SerabelisibPhase 2PIK3CAPI3-kinase p110-alpha subunit inhibitor
SonolisibPhase 2PI3-kinase class IPI3-kinase class I inhibitor
TenalisibPhase 2PIK3CD, PIK3CGPI3-kinase p110-delta subunit inhibitor
VoxtalisibPhase 2MTOR, PI3-kinase class ISerine/threonine-protein kinase mTOR inhibitor
VulolisibPhase 2——
AcalisibPhase 1PIK3CDPI3-kinase p110-delta subunit inhibitor
EganelisibPhase 1PIK3CGPI3-kinase p110-gamma subunit inhibitor
OmipalisibPhase 1PI3-kinase class I, MTORPI3-kinase class I inhibitor
PanulisibPhase 1PI3-kinase class I, MTOR, ACVRL1PI3-kinase class I inhibitor
Recilisib—PI3-kinase class IPI3-kinase class I inhibitor

Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.